The global Peptide CDMO market was valued at US$ 4805 million in 2025 and is anticipated to reach US$ 12580 million by 2032, at a CAGR of 15.0% from 2026 to 2032.

Peptide CDMO Market

Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis. A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing. CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.

The Peptide CDMO (Contract Development and Manufacturing Organization) market is driven by the increasing demand for peptide-based therapeutics. Peptides are gaining significant traction in the pharmaceutical industry due to their high specificity, targeted action, and fewer side effects compared to traditional small-molecule drugs. As a result, there is growing interest in developing and manufacturing peptides for a wide range of indications, including oncology, diabetes, cardiovascular diseases, and neurological disorders. This shift is coupled with the rise in personalized medicine, where peptides are seen as promising candidates for tailored therapies. Peptide CDMOs are playing a crucial role by providing specialized services like synthesis, purification, and formulation, enabling pharmaceutical companies to bring peptide-based drugs to market faster and more efficiently. Additionally, advancements in peptide synthesis technologies and the increasing outsourcing trend by biopharmaceutical companies are fueling growth in this sector.

Despite the positive growth drivers, the Peptide CDMO market faces several challenges. One of the main hurdles is the complexity involved in peptide synthesis and manufacturing, particularly for large-scale production. Peptides are often fragile and prone to degradation, requiring strict control over production processes, which can be both time-consuming and costly. Additionally, the high costs of peptide synthesis, purification, and formulation pose significant barriers to entry for smaller players, limiting competition and innovation in the market. Furthermore, regulatory challenges are a concern, as peptides often face more stringent requirements during the clinical development and commercialization stages compared to traditional small-molecule drugs. These challenges can result in delays in drug development and increased production costs, which could ultimately impact the profitability of peptide CDMOs.

Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively.

This report delivers a comprehensive overview of the global Peptide CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Peptide CDMO. The Peptide CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Peptide CDMO market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Peptide CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Peptide CDMO Market Report

Report Metric	Details
Report Name	Peptide CDMO Market
Accounted market size in 2025	US$ 4805 million
Forecasted market size in 2032	US$ 12580 million
CAGR	15.0%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	APIs and Intermediates FDF
Segment by Application	Commercial Academic Research Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, ScinoPharm, SN Biopharm, CBL, Piramal Pharma, CPC Scientific
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Peptide CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Peptide CDMO Market growing?

Ans: The Peptide CDMO Market witnessing a CAGR of 15.0% during the forecast period 2026-2032.

What is the Peptide CDMO Market size in 2032?

Ans: The Peptide CDMO Market size in 2032 will be US$ 12580 million.

What is the market share of major companies in Peptide CDMO Market?

Ans: The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%.

What is the Peptide CDMO Market share by region?

Ans: At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively.

Who are the main players in the Peptide CDMO Market report?

Ans: The main players in the Peptide CDMO Market are Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, ScinoPharm, SN Biopharm, CBL, Piramal Pharma, CPC Scientific

What are the Application segmentation covered in the Peptide CDMO Market report?

Ans: The Applications covered in the Peptide CDMO Market report are Commercial, Academic Research, Other

What are the Type segmentation covered in the Peptide CDMO Market report?

Ans: The Types covered in the Peptide CDMO Market report are APIs and Intermediates, FDF

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Peptide CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 APIs and Intermediates

1.2.3 FDF

1.3 Market by Application

1.3.1 Global Peptide CDMO Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Commercial

1.3.3 Academic Research

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Peptide CDMO Market Perspective (2021–2032)

2.2 Global Peptide CDMO Growth Trends by Region

2.2.1 Global Peptide CDMO Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Peptide CDMO Historic Market Size by Region (2021–2026)

2.2.3 Peptide CDMO Forecasted Market Size by Region (2027–2032)

2.3 Peptide CDMO Market Dynamics

2.3.1 Peptide CDMO Industry Trends

2.3.2 Peptide CDMO Market Drivers

2.3.3 Peptide CDMO Market Challenges

2.3.4 Peptide CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Peptide CDMO Players by Revenue

3.1.1 Global Top Peptide CDMO Players by Revenue (2021–2026)

3.1.2 Global Peptide CDMO Revenue Market Share by Players (2021–2026)

3.2 Global Top Peptide CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Peptide CDMO Revenue

3.4 Global Peptide CDMO Market Concentration Ratio

3.4.1 Global Peptide CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Peptide CDMO Revenue in 2025

3.5 Global Key Players of Peptide CDMO Head Offices and Areas Served

3.6 Global Key Players of Peptide CDMO, Products and Applications

3.7 Global Key Players of Peptide CDMO, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Peptide CDMO Breakdown Data by Type

4.1 Global Peptide CDMO Historic Market Size by Type (2021–2026)

4.2 Global Peptide CDMO Forecasted Market Size by Type (2027–2032)

5 Peptide CDMO Breakdown Data by Application

5.1 Global Peptide CDMO Historic Market Size by Application (2021–2026)

5.2 Global Peptide CDMO Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Peptide CDMO Market Size (2021–2032)

6.2 North America Peptide CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Peptide CDMO Market Size by Country (2021–2026)

6.4 North America Peptide CDMO Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Peptide CDMO Market Size (2021–2032)

7.2 Europe Peptide CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Peptide CDMO Market Size by Country (2021–2026)

7.4 Europe Peptide CDMO Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Peptide CDMO Market Size (2021–2032)

8.2 Asia-Pacific Peptide CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Peptide CDMO Market Size by Region (2021–2026)

8.4 Asia-Pacific Peptide CDMO Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Peptide CDMO Market Size (2021–2032)

9.2 Latin America Peptide CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Peptide CDMO Market Size by Country (2021–2026)

9.4 Latin America Peptide CDMO Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Peptide CDMO Market Size (2021–2032)

10.2 Middle East & Africa Peptide CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Peptide CDMO Market Size by Country (2021–2026)

10.4 Middle East & Africa Peptide CDMO Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bachem

11.1.1 Bachem Company Details

11.1.2 Bachem Business Overview

11.1.3 Bachem Peptide CDMO Introduction

11.1.4 Bachem Revenue in Peptide CDMO Business (2021–2026)

11.1.5 Bachem Recent Development

11.2 PolyPeptide

11.2.1 PolyPeptide Company Details

11.2.2 PolyPeptide Business Overview

11.2.3 PolyPeptide Peptide CDMO Introduction

11.2.4 PolyPeptide Revenue in Peptide CDMO Business (2021–2026)

11.2.5 PolyPeptide Recent Development

11.3 CordenPharma

11.3.1 CordenPharma Company Details

11.3.2 CordenPharma Business Overview

11.3.3 CordenPharma Peptide CDMO Introduction

11.3.4 CordenPharma Revenue in Peptide CDMO Business (2021–2026)

11.3.5 CordenPharma Recent Development

11.4 AmbioPharm

11.4.1 AmbioPharm Company Details

11.4.2 AmbioPharm Business Overview

11.4.3 AmbioPharm Peptide CDMO Introduction

11.4.4 AmbioPharm Revenue in Peptide CDMO Business (2021–2026)

11.4.5 AmbioPharm Recent Development

11.5 USV Peptides

11.5.1 USV Peptides Company Details

11.5.2 USV Peptides Business Overview

11.5.3 USV Peptides Peptide CDMO Introduction

11.5.4 USV Peptides Revenue in Peptide CDMO Business (2021–2026)

11.5.5 USV Peptides Recent Development

11.6 Thermofischer

11.6.1 Thermofischer Company Details

11.6.2 Thermofischer Business Overview

11.6.3 Thermofischer Peptide CDMO Introduction

11.6.4 Thermofischer Revenue in Peptide CDMO Business (2021–2026)

11.6.5 Thermofischer Recent Development

11.7 Bio Basic

11.7.1 Bio Basic Company Details

11.7.2 Bio Basic Business Overview

11.7.3 Bio Basic Peptide CDMO Introduction

11.7.4 Bio Basic Revenue in Peptide CDMO Business (2021–2026)

11.7.5 Bio Basic Recent Development

11.8 JPT

11.8.1 JPT Company Details

11.8.2 JPT Business Overview

11.8.3 JPT Peptide CDMO Introduction

11.8.4 JPT Revenue in Peptide CDMO Business (2021–2026)

11.8.5 JPT Recent Development

11.9 Genscript

11.9.1 Genscript Company Details

11.9.2 Genscript Business Overview

11.9.3 Genscript Peptide CDMO Introduction

11.9.4 Genscript Revenue in Peptide CDMO Business (2021–2026)

11.9.5 Genscript Recent Development

11.10 Xinbang Pharma

11.10.1 Xinbang Pharma Company Details

11.10.2 Xinbang Pharma Business Overview

11.10.3 Xinbang Pharma Peptide CDMO Introduction

11.10.4 Xinbang Pharma Revenue in Peptide CDMO Business (2021–2026)

11.10.5 Xinbang Pharma Recent Development

11.11 ScinoPharm

11.11.1 ScinoPharm Company Details

11.11.2 ScinoPharm Business Overview

11.11.3 ScinoPharm Peptide CDMO Introduction

11.11.4 ScinoPharm Revenue in Peptide CDMO Business (2021–2026)

11.11.5 ScinoPharm Recent Development

11.12 SN Biopharm

11.12.1 SN Biopharm Company Details

11.12.2 SN Biopharm Business Overview

11.12.3 SN Biopharm Peptide CDMO Introduction

11.12.4 SN Biopharm Revenue in Peptide CDMO Business (2021–2026)

11.12.5 SN Biopharm Recent Development

11.13 CBL

11.13.1 CBL Company Details

11.13.2 CBL Business Overview

11.13.3 CBL Peptide CDMO Introduction

11.13.4 CBL Revenue in Peptide CDMO Business (2021–2026)

11.13.5 CBL Recent Development

11.14 Piramal Pharma

11.14.1 Piramal Pharma Company Details

11.14.2 Piramal Pharma Business Overview

11.14.3 Piramal Pharma Peptide CDMO Introduction

11.14.4 Piramal Pharma Revenue in Peptide CDMO Business (2021–2026)

11.14.5 Piramal Pharma Recent Development

11.15 CPC Scientific

11.15.1 CPC Scientific Company Details

11.15.2 CPC Scientific Business Overview

11.15.3 CPC Scientific Peptide CDMO Introduction

11.15.4 CPC Scientific Revenue in Peptide CDMO Business (2021–2026)

11.15.5 CPC Scientific Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Peptide CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of APIs and Intermediates

Table 3. Key Players of FDF

Table 4. Global Peptide CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 5. Global Peptide CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 6. Global Peptide CDMO Market Size by Region (US$ Million), 2021–2026

Table 7. Global Peptide CDMO Market Share by Region (2021–2026)

Table 8. Global Peptide CDMO Forecasted Market Size by Region (US$ Million), 2027–2032

Table 9. Global Peptide CDMO Market Share by Region (2027–2032)

Table 10. Peptide CDMO Market Trends

Table 11. Peptide CDMO Market Drivers

Table 12. Peptide CDMO Market Challenges

Table 13. Peptide CDMO Market Restraints

Table 14. Global Peptide CDMO Revenue by Players (US$ Million), 2021–2026

Table 15. Global Peptide CDMO Market Share by Players (2021–2026)

Table 16. Global Top Peptide CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Peptide CDMO Revenue, 2025

Table 17. Ranking of Global Top Peptide CDMO Companies by Revenue (US$ Million) in 2025

Table 18. Global 5 Largest Players Market Share by Peptide CDMO Revenue (CR5 and HHI), 2021–2026

Table 19. Global Key Players of Peptide CDMO, Headquarters and Area Served

Table 20. Global Key Players of Peptide CDMO, Products and Applications

Table 21. Global Key Players of Peptide CDMO, Date of General Availability (GA)

Table 22. Mergers and Acquisitions, Expansion Plans

Table 23. Global Peptide CDMO Market Size by Type (US$ Million), 2021–2026

Table 24. Global Peptide CDMO Revenue Market Share by Type (2021–2026)

Table 25. Global Peptide CDMO Forecasted Market Size by Type (US$ Million), 2027–2032

Table 26. Global Peptide CDMO Revenue Market Share by Type (2027–2032)

Table 27. Global Peptide CDMO Market Size by Application (US$ Million), 2021–2026

Table 28. Global Peptide CDMO Revenue Market Share by Application (2021–2026)

Table 29. Global Peptide CDMO Forecasted Market Size by Application (US$ Million), 2027–2032

Table 30. Global Peptide CDMO Revenue Market Share by Application (2027–2032)

Table 31. North America Peptide CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 32. North America Peptide CDMO Market Size by Country (US$ Million), 2021–2026

Table 33. North America Peptide CDMO Market Size by Country (US$ Million), 2027–2032

Table 34. Europe Peptide CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 35. Europe Peptide CDMO Market Size by Country (US$ Million), 2021–2026

Table 36. Europe Peptide CDMO Market Size by Country (US$ Million), 2027–2032

Table 37. Asia-Pacific Peptide CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 38. Asia-Pacific Peptide CDMO Market Size by Region (US$ Million), 2021–2026

Table 39. Asia-Pacific Peptide CDMO Market Size by Region (US$ Million), 2027–2032

Table 40. Latin America Peptide CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 41. Latin America Peptide CDMO Market Size by Country (US$ Million), 2021–2026

Table 42. Latin America Peptide CDMO Market Size by Country (US$ Million), 2027–2032

Table 43. Middle East & Africa Peptide CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 44. Middle East & Africa Peptide CDMO Market Size by Country (US$ Million), 2021–2026

Table 45. Middle East & Africa Peptide CDMO Market Size by Country (US$ Million), 2027–2032

Table 46. Bachem Company Details

Table 47. Bachem Business Overview

Table 48. Bachem Peptide CDMO Product

Table 49. Bachem Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 50. Bachem Recent Development

Table 51. PolyPeptide Company Details

Table 52. PolyPeptide Business Overview

Table 53. PolyPeptide Peptide CDMO Product

Table 54. PolyPeptide Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 55. PolyPeptide Recent Development

Table 56. CordenPharma Company Details

Table 57. CordenPharma Business Overview

Table 58. CordenPharma Peptide CDMO Product

Table 59. CordenPharma Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 60. CordenPharma Recent Development

Table 61. AmbioPharm Company Details

Table 62. AmbioPharm Business Overview

Table 63. AmbioPharm Peptide CDMO Product

Table 64. AmbioPharm Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 65. AmbioPharm Recent Development

Table 66. USV Peptides Company Details

Table 67. USV Peptides Business Overview

Table 68. USV Peptides Peptide CDMO Product

Table 69. USV Peptides Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 70. USV Peptides Recent Development

Table 71. Thermofischer Company Details

Table 72. Thermofischer Business Overview

Table 73. Thermofischer Peptide CDMO Product

Table 74. Thermofischer Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 75. Thermofischer Recent Development

Table 76. Bio Basic Company Details

Table 77. Bio Basic Business Overview

Table 78. Bio Basic Peptide CDMO Product

Table 79. Bio Basic Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 80. Bio Basic Recent Development

Table 81. JPT Company Details

Table 82. JPT Business Overview

Table 83. JPT Peptide CDMO Product

Table 84. JPT Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 85. JPT Recent Development

Table 86. Genscript Company Details

Table 87. Genscript Business Overview

Table 88. Genscript Peptide CDMO Product

Table 89. Genscript Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 90. Genscript Recent Development

Table 91. Xinbang Pharma Company Details

Table 92. Xinbang Pharma Business Overview

Table 93. Xinbang Pharma Peptide CDMO Product

Table 94. Xinbang Pharma Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 95. Xinbang Pharma Recent Development

Table 96. ScinoPharm Company Details

Table 97. ScinoPharm Business Overview

Table 98. ScinoPharm Peptide CDMO Product

Table 99. ScinoPharm Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 100. ScinoPharm Recent Development

Table 101. SN Biopharm Company Details

Table 102. SN Biopharm Business Overview

Table 103. SN Biopharm Peptide CDMO Product

Table 104. SN Biopharm Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 105. SN Biopharm Recent Development

Table 106. CBL Company Details

Table 107. CBL Business Overview

Table 108. CBL Peptide CDMO Product

Table 109. CBL Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 110. CBL Recent Development

Table 111. Piramal Pharma Company Details

Table 112. Piramal Pharma Business Overview

Table 113. Piramal Pharma Peptide CDMO Product

Table 114. Piramal Pharma Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 115. Piramal Pharma Recent Development

Table 116. CPC Scientific Company Details

Table 117. CPC Scientific Business Overview

Table 118. CPC Scientific Peptide CDMO Product

Table 119. CPC Scientific Revenue in Peptide CDMO Business (US$ Million), 2021–2026

Table 120. CPC Scientific Recent Development

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

Table 124. Authors List of This Report

List of Figures

Figure 1. Peptide CDMO Picture

Figure 2. Global Peptide CDMO Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Peptide CDMO Market Share by Type: 2025 vs 2032

Figure 4. APIs and Intermediates Features

Figure 5. FDF Features

Figure 6. Global Peptide CDMO Market Size by Application (US$ Million), 2021–2032

Figure 7. Global Peptide CDMO Market Share by Application: 2025 vs 2032

Figure 8. Commercial Case Studies

Figure 9. Academic Research Case Studies

Figure 10. Other Case Studies

Figure 11. Peptide CDMO Report Years Considered

Figure 12. Global Peptide CDMO Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 13. Global Peptide CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global Peptide CDMO Market Share by Region: 2025 vs 2032

Figure 15. Global Peptide CDMO Market Share by Players in 2025

Figure 16. Global Peptide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 17. The Top 10 and 5 Players Market Share by Peptide CDMO Revenue in 2025

Figure 18. North America Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 19. North America Peptide CDMO Market Share by Country (2021–2032)

Figure 20. United States Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 21. Canada Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Europe Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Europe Peptide CDMO Market Share by Country (2021–2032)

Figure 24. Germany Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. France Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. U.K. Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. Italy Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Russia Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Ireland Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Asia-Pacific Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Asia-Pacific Peptide CDMO Market Share by Region (2021–2032)

Figure 32. China Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Japan Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. South Korea Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Southeast Asia Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. India Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Australia & New Zealand Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Latin America Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Latin America Peptide CDMO Market Share by Country (2021–2032)

Figure 40. Mexico Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Brazil Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Middle East & Africa Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Middle East & Africa Peptide CDMO Market Share by Country (2021–2032)

Figure 44. Israel Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Saudi Arabia Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. UAE Peptide CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Bachem Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 48. PolyPeptide Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 49. CordenPharma Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 50. AmbioPharm Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 51. USV Peptides Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 52. Thermofischer Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 53. Bio Basic Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 54. JPT Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 55. Genscript Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 56. Xinbang Pharma Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 57. ScinoPharm Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 58. SN Biopharm Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 59. CBL Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 60. Piramal Pharma Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 61. CPC Scientific Revenue Growth Rate in Peptide CDMO Business (2021–2026)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Peptide Synthesis CMO Market Research Report 2025

Global Peptide Synthesis Market Insights Forecast to 2030

Global Peptide Synthesis Service Market Insights Forecast to 2030

Global Chemical Synthesis Peptide Drugs Market Research Report 2024

Global Amino Acids for Peptide Drug Synthesis Market Research Report 2025

Global Peptide Synthesis CDMO Services Market Research Report 2024

Global Peptide Drug Synthesis Reagents Market Research Report 2025

Global Peptide Drug CDMO Market Research Report 2024

Global Protein and Peptide Therapeutics Market Research Report 2025

Peptide Therapeutics Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peptide Synthesis Reagent Market Research Report 2024

Peptide based Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Injection Peptide Drug Market Research Report 2025

Peptide Synthesis Equipment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peptide CDMO Services Market Research Report 2025

Peptide Coupling Reagent Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Synthesis Polypeptide Drugs Market Insights Forecast to 2030

Peptide Synthesis Instruments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Peptide Building Block Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions